Back to search
FDAFDA · Food and drugs·Recall number D-0460-2025

Celecoxib Capsules, 200 mg, 50 Capsules (5x10) Unit Dose per carton, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478. NDC 50268-169-15

Published June 18, 2025 · Recall initiated: May 13, 2025

Summary

FDA records drug Class II recall D-0460-2025, published June 18, 2025 and initiated May 13, 2025. Recalling firm: AvKARE; Status: Ongoing; Reported quantity: 3,817 50-count cartons; Lot: Lot #47881, Exp 05/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules

What to do

Voluntary: Firm initiated · Letter

Get an email if CELECOXIB has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CELECOXIB
Manufacturer
AvKARE
Distributor
Nationwide in the USA
Lot
Lot #47881, Exp 05/31/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Celecoxib Capsules, 200 mg, 50 Capsules (5x10) Unit Dose per carton, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478. NDC 50268-169-15 recalled?

Yes. FDA published recall D-0460-2025 on June 18, 2025. Reported hazard: Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CELECOXIB.